3rd Circ. Says Cash Not Key For Pay-For-Delay Suits
The Third Circuit ruled Friday that pharmaceutical patent settlements do not need to come in the form of a cash payout from a brand to a generic to face antitrust scrutiny...To view the full article, register now.
Already a subscriber? Click here to view full article